Pre-transplant measurable residual disease by flow cytometry is an independent prognostic factor in pediatric acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation - Top-Institutions - MDSpire

Pre-transplant measurable residual disease by flow cytometry is an independent prognostic factor in pediatric acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation

  • By

  • Shaoyang Deng

  • Shan He

  • Na Song

  • Zhijun Huang

  • Benshan Zhang

  • July 17, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Center for International Blood and Marrow Transplant Research
    Center for International Blood and Marrow Transplant Research

    Milwaukee, Wisconsin

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    Hunan Children’s Hospital
    Hunan Children’s Hospital

    Changsha, Hunan

    Key Differentiators

    • Pediatric Hematology
    • Oncology

  • #3

    European Society for Blood and Marrow Transplantation
    European Society for Blood and Marrow Transplantation

    Brussels, Belgium

    Key Differentiators

    • Hematology
    • Transplantation

  • #4

    Columbia University
    Columbia University

    New York, New York

    Key Differentiators

    • Hematology
    • Oncology

  • #5

    Herbert Irving Comprehensive Cancer Center
    Herbert Irving Comprehensive Cancer Center

    New York, New York

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

Pre-transplant measurable residual disease by flow cytometry is an independent prognostic factor in pediatric acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation

  • by Shaoyang Deng, Shan He, Na Song, Zhijun Huang, Benshan Zhang

  • July 17, 2026

Related Content

Sarcopenia in breast cancer: prognostic values and emerging therapeutic strategies

Surviving CGT's Funding Winter

In the first installment of a new series on the investment environment in cell and gene therapy, Circio CEO Erik Wiklund explains how he had to get creative to raise funds in a difficult biotech market

Research progress of small molecule targeted drugs for non-small cell lung cancer